MPOX: CURRENT CHALLENGES IN DIAGNOSIS, TREATMENT, PREVENTION, AND PUBLIC HEALTH – A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6373Keywords:
Mpox, Monkeypox, MPXV, Epidemiology, Diagnosis, Treatment, Vaccination, Public HealthAbstract
Mpox (monkeypox) has emerged as a major global public health concern following the unprecedented multinational outbreaks that began in 2022. Although historically considered a neglected zoonotic disease confined mainly to endemic regions of Central and West Africa, recent epidemiological changes, international spread, and the emergence of new viral clades have highlighted significant gaps in preparedness, surveillance, and access to medical countermeasures. The clinical spectrum of mpox has also evolved, with atypical presentations increasingly reported during recent outbreaks, creating additional diagnostic challenges for clinicians.
This narrative review summarizes current evidence regarding the epidemiology, transmission, pathogenesis, clinical manifestations, diagnosis, treatment, prevention, and public health implications of mpox. Particular attention is given to limitations of existing diagnostic methods, the evolving evidence surrounding antiviral therapy, challenges associated with vaccine availability and effectiveness, and the importance of risk communication and stigma reduction strategies. The review also discusses the role of genomic surveillance, point-of-care diagnostics, and the One Health approach in strengthening future outbreak preparedness and response.
Despite substantial progress in understanding mpox since 2022, important uncertainties remain regarding long-term control strategies, equitable access to vaccines and therapeutics, and the management of emerging viral variants. Continued international collaboration, investment in surveillance infrastructure, and improved global health equity will be essential for reducing the impact of future mpox outbreaks.
References
Gessain, A., Nakoune, E., & Yazdanpanah, Y. (2022). Monkeypox. The New England Journal of Medicine, 387(19), 1783–1793. https://doi.org/10.1056/NEJMra2208860
Bunge, E. M., Hoet, B., Chen, L., Lienert, F., Weidenthaler, H., Baer, L. R., et al. (2022). The changing epidemiology of human monkeypox—A potential threat? A systematic review. PLoS Neglected Tropical Diseases, 16(2), e0010141. https://doi.org/10.1371/journal.pntd.0010141
Thornhill, J. P., Barkati, S., Walmsley, S., Rockstroh, J., Antinori, A., Harrison, L. B., et al. (2022). Monkeypox virus infection in humans across 16 countries—April–June 2022. The New England Journal of Medicine, 387(8), 679–691. https://doi.org/10.1056/NEJMoa2207323
Tarín-Vicente, E. J., Alemany, A., Agud-Dios, M., Ubals, M., Suñer, C., Antón, A., et al. (2022). Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: A prospective observational cohort study. The Lancet, 400(10353), 661–669. https://doi.org/10.1016/S0140-6736(22)01436-2
World Health Organization. (2026, June 26). Multi-country outbreak of mpox: External situation report No. 67. https://cdn.who.int/media/docs/default-source/_sage-2026/multi-country-outbreak-of-mpox--external-situation-report_67.pdf?sfvrsn=35f305d6_3&download=true
Kremer, C., Nundu, S. S., Vakaniaki, E. H., et al. (2025). Epidemiological characteristics of monkeypox virus clade Ib in the Democratic Republic of the Congo. Nature Communications, 17, 180. https://doi.org/10.1038/s41467-025-66875-6
Titanji, B. K., Tegomoh, B., Nematollahi, S., Konomos, M., & Kulkarni, P. A. (2022). Monkeypox: A contemporary review for healthcare professionals. Open Forum Infectious Diseases, 9(7), ofac310. https://doi.org/10.1093/ofid/ofac310
World Health Organization. (2022, July 23). WHO Director-General declares the multi-country outbreak of monkeypox a Public Health Emergency of International Concern. https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern
Patel, A., Bilinska, J., Tam, J. C. H., Da Silva Fontoura, D., Mason, C. Y., Daunt, A., et al. (2022). Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: Descriptive case series. BMJ, 378, e072410. https://doi.org/10.1136/bmj-2022-072410
Curaudeau, M., Besombes, C., Nakouné, E., Fontanet, A., Gessain, A., & Hassanin, A. (2023). Identifying the most probable mammal reservoir hosts for monkeypox virus based on ecological niche comparisons. Viruses, 15(3), 727. https://doi.org/10.3390/v15030727
Bonilla-Aldana, D. K., Bonilla-Aldana, J. L., Ulloque-Badaracco, J. R., Al-Kassab-Córdova, A., Hernandez-Bustamante, E. A., Alarcon-Braga, E. A., Benites-Zapata, V. A., Copaja-Corzo, C., Silva-Cajaleon, K., & Rodriguez-Morales, A. J. (2024). Mpox infection in animals: A systematic review and meta-analysis. Journal of Infection and Public Health, 17(7), 102431. https://doi.org/10.1016/j.jiph.2024.04.015
Hayman, D. T. S., Koopmans, M. P. G., Cunningham, A. A., Fooks, A. R., Wood, J. L. N., & Grant, R. (2025). Mpox: A case study for a One Health approach to infectious disease prevention. One Health, 20, 101059. https://doi.org/10.1016/j.onehlt.2025.101059
Alshamrani, M. M., et al. (2025). Routes of transmission of mpox by virus clade and geographic distribution: A systematic review. Journal of Infection and Public Health, 18(12), 102985. https://doi.org/10.1016/j.jiph.2025.102985
UK Health Security Agency. (2025). Mpox routes of transmission: Rapid evidence summary. https://assets.publishing.service.gov.uk/media/69e1f1cb20b52e4144868985/mpox-transmission-routes-rapid-evidence-summary.pdf
Ogoina, D., Damon, I., Nakoune, E., et al. (2023). Clinical review of human mpox. Clinical Microbiology and Infection, 29(12), 1493–1501. https://doi.org/10.1016/j.cmi.2023.09.004
Kumar, N., Acharya, A., Gendelman, H. E., & Byrareddy, S. N. (2022). The 2022 outbreak and the pathobiology of the monkeypox virus. Journal of Autoimmunity, 131, 102855. https://doi.org/10.1016/j.jaut.2022.102855
Moraes-Cardoso, I., Benet, S., Carabelli, J., Perez-Zsolt, D., Mendoza, A., Rivero, A., Alemany, A., Descalzo, V., Alarcón-Soto, Y., Grifoni, A., Sette, A., Moltó, J., Marc, A., Marks, M., Mitjà, O., Brander, C., Paredes, R., Izquierdo-Useros, N., Carrillo, J., Suñer, C., . . . MoViE-Immune Study Group. (2024). Immune responses associated with mpox viral clearance in men with and without HIV in Spain: A multisite, observational, prospective cohort study. The Lancet Microbe, 5(8), 100859. https://doi.org/10.1016/S2666-5247(24)00074-0
Mitjà, O., Alemany, A., Marks, M., Lezama Mora, J. I., Rodríguez-Aldama, J. C., Torres Silva, M. S., Corral Herrera, E. A., Crabtree-Ramirez, B., Blanco, J. L., Girometti, N., Mazzotta, V., Hazra, A., Silva, M., Montenegro-Idrogo, J. J., Gebo, K., Ghosn, J., Peña Vázquez, M. F., Matos Prado, E., Unigwe, U., . . . SHARE-NET Writing Group. (2023). Mpox in people with advanced HIV infection: A global case series. The Lancet, 401(10380), 939–949. https://doi.org/10.1016/S0140-6736(23)00273-8
Pinnetti, C., Cimini, E., Mazzotta, V., et al. (2024). Mpox as AIDS-defining event with a severe and protracted course: Clinical, immunological, and virological implications. The Lancet Infectious Diseases, 24(2), e67–e69. https://doi.org/10.1016/S1473-3099(23)00482-6
Vakaniaki, E. H., Barhishindi, I., Mubiala, A., et al. (2026). Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: A pooled, prospective cohort study. The Lancet, 407(10525), 256–266. https://doi.org/10.1016/S0140-6736(25)02309-8
Pinto-Pulido, E. L., Fernández-Parrado, M., & Rodríguez-Cuadrado, F. J. (2023). Atypical clinical features of mpox (monkeypox): A diagnostic challenge—Reply. Anais Brasileiros de Dermatologia, 98(5), 734–735. https://doi.org/10.1016/j.abd.2023.04.002
Bourner, J., Garcia-Gallo, E., Mbrenga, F., Boum, Y., Nakouné, E., Paterson, A., Jones, B., Olliaro, P., & Rojek, A. (2024). Challenges in clinical diagnosis of clade I mpox: Highlighting the need for enhanced diagnostic approaches. PLoS Neglected Tropical Diseases, 18(6), e0012087. https://doi.org/10.1371/journal.pntd.0012087
da Silva, S. J. R., Kohl, A., Pena, L., et al. (2023). Clinical and laboratory diagnosis of monkeypox (mpox): Current status and future directions. iScience, 26(6), 106759. https://doi.org/10.1016/j.isci.2023.106759
Li, Y., Olson, V. A., Laue, T., Laker, M. T., & Damon, I. K. (2006). Detection of monkeypox virus with real-time PCR assays. Journal of Clinical Virology, 36(3), 194–203. https://doi.org/10.1016/j.jcv.2006.03.012
Salimović-Bešić, I., Zvizdić, E., Čengić, A., & Delić-Latinović, A. (2024). Mpox virus DNA detection in different clinical specimens: Tertiary-level laboratory experience, Bosnia and Herzegovina, 2022. Diagnostic Microbiology and Infectious Disease, 109(2), 116268. https://doi.org/10.1016/j.diagmicrobio.2024.116268
World Health Organization. (2024). Diagnostic testing and testing strategies for mpox. https://www.who.int/publications/i/item/B09166
Adler, H., Gould, S., Hine, P., Snell, L. B., Wong, W., Houlihan, C. F., Osborne, J. C., Rampling, T., Beadsworth, M. B., Duncan, C. J. A., Dunning, J., Fletcher, T. E., Hunter, E. R., Jacobs, M., Khoo, S. H., Newsholme, W., Porter, D., Porter, R. J., Ratcliffe, L., . . . NHS England High Consequence Infectious Diseases Network. (2022). Clinical features and management of human monkeypox: A retrospective observational study in the UK. The Lancet Infectious Diseases, 22(8), 1153–1162. https://doi.org/10.1016/S1473-3099(22)00228-6
Hallo-Carrasco, A., et al. (2023). Pain associated with monkeypox virus: A rapid review. Cureus, 15(2), e35569. https://doi.org/10.7759/cureus.35569
Centers for Disease Control and Prevention. (2026). Caring for patients with monkeypox. https://www.cdc.gov/monkeypox/hcp/clinical-care/index.html
Grosenbach, D. W., Honeychurch, K., Rose, E. A., Chinsangaram, J., Frimm, A., Maiti, B., et al. (2018). Oral tecovirimat for the treatment of smallpox. The New England Journal of Medicine, 379(1), 44–53. https://doi.org/10.1056/NEJMoa1705688
Zucker, J., et al. (2026). Tecovirimat for the treatment of mpox. The New England Journal of Medicine, 394(9), 884–895. https://doi.org/10.1056/NEJMoa2506495
PALM007 Writing Group. (2025). Tecovirimat for clade I MPXV infection in the Democratic Republic of the Congo. The New England Journal of Medicine, 392(15), 1484–1496. https://doi.org/10.1056/NEJMoa2412439
Fine, P. E. M., Jezek, Z., Grab, B., & Dixon, H. (1988). The transmission potential of monkeypox virus in human populations. International Journal of Epidemiology, 17(3), 643–650. https://doi.org/10.1093/ije/17.3.643
Rimoin, A. W., Mulembakani, P. M., Johnston, S. C., Lloyd Smith, J. O., Kisalu, N. K., Kinkela, T. L., et al. (2010). Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proceedings of the National Academy of Sciences of the United States of America, 107(37), 16262–16267. https://doi.org/10.1073/pnas.1005769107
Centers for Disease Control and Prevention. (2026). Vaccine for monkeypox prevention in the United States. https://www.cdc.gov/monkeypox/hcp/vaccine-considerations/?CDC_AAref_Val=https://www.cdc.gov/poxvirus/mpox/interim-considerations/overview.html
Payne, A. B., Ray, L. C., Kugeler, K. J., et al. (2022). Incidence of monkeypox among unvaccinated persons compared with persons receiving ≥1 JYNNEOS vaccine dose—32 U.S. jurisdictions, July 31–September 3, 2022. MMWR Morbidity and Mortality Weekly Report, 71(40), 1278–1282. https://doi.org/10.15585/mmwr.mm7140e3
European Centre for Disease Prevention and Control. (2025). Rapid scientific advice on public health measures for mpox (2024–2025): Vaccination. https://www.ecdc.europa.eu/en/infectious-disease-topics/mpox/rapid-scientific-advice-public-health-measures-mpox-2024-2025
World Health Organization. (2024). Smallpox and mpox (orthopoxviruses): WHO position paper, August 2024. Weekly Epidemiological Record, 99(34), 429–456. https://www.who.int/publications/i/item/who-wer-9934-429-456
Cynthia, A. N., & Nchanji, G. T. (2025). MPOX outbreak in Africa: The urgent need for local manufacturing of the vaccine and decolonized health systems. BMC Public Health, 25(1), 3838. https://doi.org/10.1186/s12889-025-25120-x
European Centre for Disease Prevention and Control, & World Health Organization Regional Office for Europe. (2025). Joint ECDC-WHO Regional Office for Europe mpox surveillance surveillance bulletin. https://monkeypoxreport.ecdc.europa.eu/
World Health Organization. (2023). Risk communication and community engagement (RCCE) for mpox outbreaks and response. https://www.who.int/publications/i/item/WHO-MPX-RCCE-2022.1
Jaleel, A., Farid, G., Irfan, H., et al. (2024). A systematic review on the mental health status of patients infected with monkeypox virus. Journal of the Korean Academy of Child and Adolescent Psychiatry, 35, 107–118. https://doi.org/10.5765/jkacap.230064
Orsini, D., Sartini, M., Spagnolo, A. M., Cristina, M. L., & Martini, M. (2024). Mpox: “The stigma is as dangerous as the virus”: Historical, social, ethical issues and future forthcoming. Journal of Preventive Medicine and Hygiene, 64(4), E398–E404. https://doi.org/10.15167/2421-4248/jpmh2023.64.4.3144
Liu, Y., Zhang, J., & Cai, Y. (2025). Mpox-related stigma and healthcare-seeking behavior among men who have sex with men. Global Health Research and Policy, 10(1), 16. https://doi.org/10.1186/s41256-025-00418-w
Linares-Navarro, R., Sanz-Muñoz, I., Onecha-Vallejo, V., Fernández-Espinilla, V., Eiros, J. M., Castrodeza-Sanz, J., & Prada-García, C. (2025). Psychosocial impact and stigma on men who have sex with men due to monkeypox. Frontiers in Public Health, 13, 1479680. https://doi.org/10.3389/fpubh.2025.1479680
Nachega, J. B., Sam-Agudu, N. A., Ogoina, D., et al. (2024). The surge of mpox in Africa: A call for action. The Lancet Global Health, 12(7), e1086–e1088. https://doi.org/10.1016/S2214-109X(24)00187-6
Ndembi, N., Folayan, M. O., Ngongo, N., et al. (2024). Mpox outbreaks in Africa constitute a public health emergency of continental security. The Lancet Global Health, 12(10), e1577–e1579. https://doi.org/10.1016/S2214-109X(24)00363-2
Yigci, D., Ergönül, Ö., & Tasoglu, S. (2025). Mpox diagnosis at POC. Trends in Biotechnology, 43(10), 2427–2439. https://doi.org/10.1016/j.tibtech.2025.04.015
Kurosawa, N., Ozawa, T., Ozawa, K., Shimojima, M., Kawahara, M., Kasuya, F., Okada, W., Nagashima, M., Sadamasu, K., Itamochi, M., Tani, H., Morinaga, Y., Yuhara, K., Okamoto, J., Ichikawa, H., Kawahata, T., Yamazaki, T., & Isobe, M. (2025). Development and clinical evaluation of a MPXV antigen-detecting rapid diagnostic test. Journal of Virological Methods, 337, 115164. https://doi.org/10.1016/j.jviromet.2025.115164
Sunchatawirul, K., Yingyong, T., Nitiyanontakij, R., Suwanvattana, P., Reawrang, S., Pongpirul, W., Charoenpong, L., Chuxnum, T., & Prasithsirikul, W. (2026). Building genomic epidemiology capacity for mpox virus and other viral pathogenic detection for public health preparedness and response. International Journal of Infectious Diseases, 163, 108192. https://doi.org/10.1016/j.ijid.2025.108192
Pischel, L., Martini, B. A., Yu, N., Cacesse, D., Tracy, M., Kharbanda, K., Ahmed, N., Patel, K. M., Grimshaw, A. A., Malik, A. A., Goshua, G., & Omer, S. B. (2024). Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis. Vaccine, 42(25), 126053. https://doi.org/10.1016/j.vaccine.2024.06.021
Berry, M. T., Khan, S. R., Schlub, T. E., Notaras, A., Kunasekaran, M., Grulich, A. E., MacIntyre, C. R., Davenport, M. P., & Khoury, D. S. (2024). Predicting vaccine effectiveness for mpox. Nature Communications, 15(1), 3856. https://doi.org/10.1038/s41467-024-48180-w
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Wojciech Kopyciński, Olaf Krawczyk, Norbert Krawczyk, Piotr Wilczkowski, Natalia Krzysztofek, Monika Kamela, Katarzyna Boszczyk, Małgorzata Grzybowska, Adrianna Baran, Aleksandra Palka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
